What Do Multinational Pharma Companies Know that Equity Investors Don’t?

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Thematic (Sector/Industry)

United states Pharmaceuticals, biotechnology and life sciences / Thematic (Sector/Industry)

<ul>
<li>In just over 10 years, China has become the second largest developer of new drugs.</li>
<li>This massive increase in of new drug development is driven by its almost leading position in clinical trials.</li>
<li>We believe that this huge drive will allow China to become one of the leading exporters of innovative drugs.</li>
</ul>


In just over 10 years, China has become the second largest developer of new drugs.
This massive increase in of new drug development is driven by its almost leading position in clinical trials.
We believe that this huge drive will allow China to become one of the leading exporters of innovative drugs.


Chinese Pharma Global Outlook Part 1: Expect Exports to Increase Significantly over the Next Decade